{"id":11655,"date":"2015-02-11T15:08:09","date_gmt":"2015-02-11T14:08:09","guid":{"rendered":"http:\/\/blog.cofb.cat\/?p=11655"},"modified":"2015-02-11T15:08:09","modified_gmt":"2015-02-11T14:08:09","slug":"nous-tractaments-per-a-lhepatitis-c","status":"publish","type":"post","link":"https:\/\/www.cofb.org\/es\/2015\/02\/11\/nous-tractaments-per-a-lhepatitis-c\/","title":{"rendered":"Nuevos tratamientos para la hepatitis C"},"content":{"rendered":"<p>La gran mayor\u00eda de medios de comunicaci\u00f3n se est\u00e1n haciendo eco del debate que est\u00e1n generando los nuevos tratamientos para la hepatitis C, tanto por su eficacia como por el coste que supone en el sistema sanitario. La hepatitis C es una enfermedad infecciosa que afecta exclusivamente al h\u00edgado y que est\u00e1 producida por el virus VHC. Antes de identificarse este virus, en 1988, esta enfermedad recib\u00eda el nombre de hepatitis no A no B. A diferencia de la hepatitis A y B,<b> no existe vacuna para prevenir la hepatitis C. <\/b>Este virus es una de las principales causas de trasplante de h\u00edgado en Catalu\u00f1a.<\/p>\n<p>El 20% de los casos agudos se curan espont\u00e1neamente, pero <b>la mayor\u00eda de las hepatitis C evolucionan hacia la cronicidad<\/b>. En los casos de hepatitis cr\u00f3nica, ha sido tratada durante muchos a\u00f1os con biterapia a base de interfer\u00f3n y ribavirina durante seis o doce meses, con unos resultados de eficacia en torno al 55-60% y con efectos adversos frecuentes.<\/p>\n<p>Desde hace unos tres a\u00f1os, han aparecido nuevos f\u00e1rmacos inhibidores de la proteasa que revolucionan el tratamiento y que, a\u00f1adidos a la biterapia, alcanzan <b>curaciones de la enfermedad en torno al 80%.<\/b> Estamos hablando de <b>boceprevir, telaprevir y simeprevir<\/b>, tratamientos que cuestan alrededor de los 25.000\u20ac. Sin embargo, la industria farmac\u00e9utica ha sacado al mercado a otros grupos de medicamentos orales como los inhibidores de la polimerasa (sofosbuvir) o los nuevos inhibidores de la prote\u00edna NS5A (daclatasvir). Pronto saldr\u00e1n al mercado nuevos f\u00e1rmacos con combinaci\u00f3n: ombitasvir, paritaprevir\/ritonavir, dasabuvir y ledipasvir.<\/p>\n<figure id=\"attachment_11658\" aria-describedby=\"caption-attachment-11658\" style=\"width: 375px\" class=\"wp-caption alignleft\"><img fetchpriority=\"high\" decoding=\"async\" class=\"wp-image-11658\" alt=\"curshepatitis\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2015\/02\/curshepatitis.jpg\" width=\"375\" height=\"186\" \/><figcaption id=\"caption-attachment-11658\" class=\"wp-caption-text\">De izquierda a derecha, la doctora Londo\u00f1o, el doctor Mallolas y la doctora Gorgues<\/figcaption><\/figure>\n<p>Con el objetivo de profundizar en el conocimiento del tratamiento del VHC, conocer las novedades terap\u00e9uticas y valorar el factor econ\u00f3mico de los nuevos tratamientos, el Colegio, conjuntamente con la Sociedad Catalana de Farmacia Cl\u00ednica (SCFC), organizaron el curso \u201c Actualizaci\u00f3n del tratamiento de la infecci\u00f3n por VHC\u201d el 11 de diciembre. Se llev\u00f3 a cabo una reflexi\u00f3n conjunta con distintos especialistas con puntos de vista diversos sobre el papel de estos tratamientos en terap\u00e9utica teniendo en cuenta aspectos de efectividad y coste-efectividad.<\/p>\n<div class=\"box shadow\">&quot;Un porcentaje elevado de pacientes VIH tambi\u00e9n se encuentran infectados por el VHC y es necesario tratar ambos virus. El impacto presupuestario de estos tratamientos no es despreciable&quot;, explica <strong>Tom\u00e0s Casasin, vocal de Hospitales del COFB<\/strong> y coordinador del curso.<\/div>\n<p>La <b>doctora Mar\u00eda Carlota Londo\u00f1o<\/b>, hepat\u00f3loga del Hospital Cl\u00ednic de Barcelona expuso extensamente los tratamientos actuales m\u00e1s recomendados seg\u00fan las gu\u00edas de pr\u00e1ctica cl\u00ednica disponibles y la duraci\u00f3n de tratamiento en funci\u00f3n de las caracter\u00edsticas del paciente a tratar: genotipo, grado de fibrosis, naive o pretratado y, en este caso, en funci\u00f3n de la respuesta lograda.<\/p>\n<p>El <b>doctor Josep Mallolas<\/b>, jefe del Hospital de D\u00eda de VIH del Hospital, present\u00f3 los \u00faltimos estudios del tratamiento del paciente coinfectados con los \u00faltimos f\u00e1rmacos aparecidos y comentados. Por \u00faltimo, la <b>doctora Maria Queralt Gorgues<\/b>, jefe de Servicio de Farmacia del Hospital Universitario Parc Taul\u00ed de Sabadell, expuso la repercusi\u00f3n econ\u00f3mica del tratamiento de la hepatitis C en el contexto del programa de medicaci\u00f3n hospitalaria de dispensaci\u00f3n ambulatoria (MHDA) y de los nuevos sistemas de financiaci\u00f3n donde la industria se compromete a abrir los costes del tratamiento en caso de que \u00e9stos sean superiores al presupuesto fijado por el Ministerio.<\/p>\n<p style=\"text-align: center;\"><a href=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2015\/02\/curs_hepatitis.jpg\"><img decoding=\"async\" class=\"wp-image-11657 aligncenter\" alt=\"curs_hepatitis\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2015\/02\/curs_hepatitis.jpg\" width=\"506\" height=\"290\" \/><\/a><\/p>\n<div class=\"box shadow\">&quot;El tratamiento de la hepatitis C es un tema de actualidad apasionante y la activa participaci\u00f3n del p\u00fablico asistente lo dej\u00f3 patente. Su tratamiento cambiar\u00e1 nuevamente en un futuro muy cercano para conseguir la curaci\u00f3n de una enfermedad que provoca la mayor parte de hepatocarcinomas y de transplantes hep\u00e1ticos. Asimismo, la situaci\u00f3n econ\u00f3mica actual, todav\u00eda hace m\u00e1s necesaria la determinaci\u00f3n f\u00e1rmacos m\u00e1s coste-efectivos\u201d, explica Casas\u00edn.<\/div>\n<p><span style=\"text-decoration: underline;\"><b><a href=\"http:\/\/canalsalut.gencat.cat\/ca\/home_ciutadania\/salut_az\/h\/hepatitis_c\/\" target=\"_blank\" rel=\"noopener\">M\u00e1s informaci\u00f3n sobre la hepatitis C en el Canal Salud de la Generalitat<\/a><\/b><\/span><\/p>\n<p style=\"text-align: right;\"><strong>Con el patrocinio de:<\/strong><\/p>\n<p style=\"text-align: right;\"><a href=\"http:\/\/www.janssen.es\/\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" class=\"size-full wp-image-6780 alignright\" alt=\"janssen_logo\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2014\/06\/janssen_logo.jpg\" width=\"100\" height=\"49\" \/><\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>La gran mayor\u00eda de medios de comunicaci\u00f3n se est\u00e1n haciendo eco del debate que est\u00e1n generando los nuevos tratamientos para la hepatitis C, tanto por su eficacia como por el coste que supone en el sistema sanitario. La hepatitis C es una enfermedad infecciosa que afecta exclusivamente al h\u00edgado y que est\u00e1 producida [\u2026]<\/p>","protected":false},"author":1,"featured_media":11658,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[57],"tags":[480,218],"class_list":["post-11655","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-mon-collegial","tag-farmacia-hospitalaria","tag-hepatitis"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Nous tractaments per a l\u2019hepatitis C - Col\u00b7legi de Farmac\u00e8utics de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/novaorg.cofb.net\/2015\/02\/11\/nous-tractaments-per-a-lhepatitis-c\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nous tractaments per a l\u2019hepatitis C - Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"og:description\" content=\"La gran majoria de mitjans de comunicaci\u00f3 s\u2019estan fent ress\u00f2 del debat que estan generant els nous tractaments per a l&#8217;hepatitis C, tant per la seva efic\u00e0cia com pel cost que suposa al sistema sanitari. L\u2019hepatitis C \u00e9s una malaltia infecciosa que afecta exclusivament el fetge i que est\u00e0 produ\u00efda [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/novaorg.cofb.net\/2015\/02\/11\/nous-tractaments-per-a-lhepatitis-c\/\" \/>\n<meta property=\"og:site_name\" content=\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-02-11T14:08:09+00:00\" \/>\n<meta name=\"author\" content=\"wpAdminCofbOrg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:site\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"wpAdminCofbOrg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/02\/11\/nous-tractaments-per-a-lhepatitis-c\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/02\/11\/nous-tractaments-per-a-lhepatitis-c\/\"},\"author\":{\"name\":\"wpAdminCofbOrg\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\"},\"headline\":\"Nous tractaments per a l\u2019hepatitis C\",\"datePublished\":\"2015-02-11T14:08:09+00:00\",\"dateModified\":\"2015-02-11T14:08:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/02\/11\/nous-tractaments-per-a-lhepatitis-c\/\"},\"wordCount\":717,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/02\/11\/nous-tractaments-per-a-lhepatitis-c\/#primaryimage\"},\"thumbnailUrl\":\"\",\"keywords\":[\"farm\u00e0cia hospital\u00e0ria\",\"hepatitis\"],\"articleSection\":[\"M\u00f3n col\u00b7legial\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/novaorg.cofb.net\/2015\/02\/11\/nous-tractaments-per-a-lhepatitis-c\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/02\/11\/nous-tractaments-per-a-lhepatitis-c\/\",\"url\":\"https:\/\/novaorg.cofb.net\/2015\/02\/11\/nous-tractaments-per-a-lhepatitis-c\/\",\"name\":\"Nous tractaments per a l\u2019hepatitis C - Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/02\/11\/nous-tractaments-per-a-lhepatitis-c\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/02\/11\/nous-tractaments-per-a-lhepatitis-c\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2015-02-11T14:08:09+00:00\",\"dateModified\":\"2015-02-11T14:08:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/02\/11\/nous-tractaments-per-a-lhepatitis-c\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/novaorg.cofb.net\/2015\/02\/11\/nous-tractaments-per-a-lhepatitis-c\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/02\/11\/nous-tractaments-per-a-lhepatitis-c\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/02\/11\/nous-tractaments-per-a-lhepatitis-c\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/novaorg.cofb.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nous tractaments per a l\u2019hepatitis C\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cofb.org\/#website\",\"url\":\"https:\/\/www.cofb.org\/\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cofb.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cofb.org\/#organization\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"url\":\"https:\/\/www.cofb.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"width\":500,\"height\":105,\"caption\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\",\"https:\/\/twitter.com\/farmaceuticsbcn\",\"https:\/\/www.instagram.com\/farmaceuticsbcn\/\",\"https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\",\"name\":\"wpAdminCofbOrg\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"caption\":\"wpAdminCofbOrg\"},\"sameAs\":[\"http:\/\/192.168.64.122\/wordpress\"],\"url\":\"https:\/\/www.cofb.org\/es\/author\/wpadmincofborg\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nous tractaments per a l\u2019hepatitis C - Col\u00b7legi de Farmac\u00e8utics de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/novaorg.cofb.net\/2015\/02\/11\/nous-tractaments-per-a-lhepatitis-c\/","og_locale":"es_ES","og_type":"article","og_title":"Nous tractaments per a l\u2019hepatitis C - Col\u00b7legi de Farmac\u00e8utics de Barcelona","og_description":"La gran majoria de mitjans de comunicaci\u00f3 s\u2019estan fent ress\u00f2 del debat que estan generant els nous tractaments per a l&#8217;hepatitis C, tant per la seva efic\u00e0cia com pel cost que suposa al sistema sanitari. L\u2019hepatitis C \u00e9s una malaltia infecciosa que afecta exclusivament el fetge i que est\u00e0 produ\u00efda [&hellip;]","og_url":"https:\/\/novaorg.cofb.net\/2015\/02\/11\/nous-tractaments-per-a-lhepatitis-c\/","og_site_name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","article_publisher":"https:\/\/www.facebook.com\/farmaceuticsbcn\/","article_published_time":"2015-02-11T14:08:09+00:00","author":"wpAdminCofbOrg","twitter_card":"summary_large_image","twitter_creator":"@farmaceuticsbcn","twitter_site":"@farmaceuticsbcn","twitter_misc":{"Escrito por":"wpAdminCofbOrg","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/novaorg.cofb.net\/2015\/02\/11\/nous-tractaments-per-a-lhepatitis-c\/#article","isPartOf":{"@id":"https:\/\/novaorg.cofb.net\/2015\/02\/11\/nous-tractaments-per-a-lhepatitis-c\/"},"author":{"name":"wpAdminCofbOrg","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb"},"headline":"Nous tractaments per a l\u2019hepatitis C","datePublished":"2015-02-11T14:08:09+00:00","dateModified":"2015-02-11T14:08:09+00:00","mainEntityOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2015\/02\/11\/nous-tractaments-per-a-lhepatitis-c\/"},"wordCount":717,"commentCount":0,"publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2015\/02\/11\/nous-tractaments-per-a-lhepatitis-c\/#primaryimage"},"thumbnailUrl":"","keywords":["farm\u00e0cia hospital\u00e0ria","hepatitis"],"articleSection":["M\u00f3n col\u00b7legial"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/novaorg.cofb.net\/2015\/02\/11\/nous-tractaments-per-a-lhepatitis-c\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/novaorg.cofb.net\/2015\/02\/11\/nous-tractaments-per-a-lhepatitis-c\/","url":"https:\/\/novaorg.cofb.net\/2015\/02\/11\/nous-tractaments-per-a-lhepatitis-c\/","name":"Nous tractaments per a l\u2019hepatitis C - Col\u00b7legi de Farmac\u00e8utics de Barcelona","isPartOf":{"@id":"https:\/\/www.cofb.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2015\/02\/11\/nous-tractaments-per-a-lhepatitis-c\/#primaryimage"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2015\/02\/11\/nous-tractaments-per-a-lhepatitis-c\/#primaryimage"},"thumbnailUrl":"","datePublished":"2015-02-11T14:08:09+00:00","dateModified":"2015-02-11T14:08:09+00:00","breadcrumb":{"@id":"https:\/\/novaorg.cofb.net\/2015\/02\/11\/nous-tractaments-per-a-lhepatitis-c\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/novaorg.cofb.net\/2015\/02\/11\/nous-tractaments-per-a-lhepatitis-c\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/novaorg.cofb.net\/2015\/02\/11\/nous-tractaments-per-a-lhepatitis-c\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/novaorg.cofb.net\/2015\/02\/11\/nous-tractaments-per-a-lhepatitis-c\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/novaorg.cofb.net\/"},{"@type":"ListItem","position":2,"name":"Nous tractaments per a l\u2019hepatitis C"}]},{"@type":"WebSite","@id":"https:\/\/www.cofb.org\/#website","url":"https:\/\/www.cofb.org\/","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"","publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cofb.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.cofb.org\/#organization","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","url":"https:\/\/www.cofb.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","width":500,"height":105,"caption":"Col\u00b7legi de Farmac\u00e8utics de Barcelona"},"image":{"@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/farmaceuticsbcn\/","https:\/\/twitter.com\/farmaceuticsbcn","https:\/\/www.instagram.com\/farmaceuticsbcn\/","https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/"]},{"@type":"Person","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb","name":"wpAdminCofbOrg","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","caption":"wpAdminCofbOrg"},"sameAs":["http:\/\/192.168.64.122\/wordpress"],"url":"https:\/\/www.cofb.org\/es\/author\/wpadmincofborg\/"}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"trp-custom-language-flag":false},"uagb_author_info":{"display_name":"wpAdminCofbOrg","author_link":"https:\/\/www.cofb.org\/es\/author\/wpadmincofborg\/"},"uagb_comment_info":0,"uagb_excerpt":"La gran majoria de mitjans de comunicaci\u00f3 s\u2019estan fent ress\u00f2 del debat que estan generant els nous tractaments per a l&#8217;hepatitis C, tant per la seva efic\u00e0cia com pel cost que suposa al sistema sanitari. L\u2019hepatitis C \u00e9s una malaltia infecciosa que afecta exclusivament el fetge i que est\u00e0 produ\u00efda [&hellip;]","_links":{"self":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts\/11655","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/comments?post=11655"}],"version-history":[{"count":0,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts\/11655\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/media?parent=11655"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/categories?post=11655"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/tags?post=11655"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}